AA
VRNA

ALPS Advisors’s Verona Pharma VRNA Stock Holding History

ALPS Advisors’s Portfolio VRNA Stock Details VRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-60,180
Closed -$3.82M – 1060
2025
Q1 		$3.82M Sell
60,180
-5,993
-9% -$358K 0.02% 264
2024
Q4 		$3.07M Buy
66,173
+3,595
+6% +$135K 0.02% 284
2024
Q3 		$1.8M Sell
62,578
-660
-1% -$16.2K 0.01% 379
2024
Q2 		$914K Buy
63,238
+6,236
+11% +$91K 0.01% 484
2024
Q1 		$917K Buy
57,002
+2,954
+5% +$51.1K 0.01% 506
2023
Q4 		$1.07M Sell
54,048
-4,563
-8% -$67.4K 0.01% 459
2023
Q3 		$955K Buy
58,611
+207
+0.4% +$3.99K 0.01% 466
2023
Q2 		$1.23M Buy
58,404
+8,477
+17% +$181K 0.01% 419
2023
Q1 		$1M Buy
49,927
+463
+0.9% +$10K 0.01% 470
2022
Q4 		$1.29M Buy
+49,464
New +$659K 0.01% 394

Other funds holding VRNA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $3.72B AUM 162.29% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

ALPS Advisors's VRNA Position: Q2 2025 in Review

ALPS Advisors sold out of Verona Pharma (VRNA) in Q2 2025, closing a stake of 60,180 shares — an estimated $3.82M sold.

ALPS Advisors first reported a position in VRNA in Q4 2022 and held it in 10 quarters. The position peaked at $3.82M in Q1 2025. 292 funds tracked by Wall St. Rank hold VRNA as of Q2 2025.

  • ALPS Advisors reported no remaining Verona Pharma position as of Q2 2025 after selling out during the quarter.
  • ALPS Advisors sold 60,180 Verona Pharma shares in Q2 2025, an estimated $3.82M.
  • ALPS Advisors first reported a position in Verona Pharma in Q4 2022 and held it in 10 quarters.
  • ALPS Advisors's Verona Pharma position peaked at $3.82M in Q1 2025.
  • 292 funds tracked by Wall St. Rank held Verona Pharma as of Q2 2025.

Based on ALPS Advisors's 13F filing for Q2 2025, filed 11 Aug 2025.